Thrombolysis

Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions

Retrieved on: 
Thursday, April 4, 2024
Brain, Ambient occlusion, AIS, Cerebral infarction, Patient, Stroke, Sale, Thrombolysis, Reperfusion, FDA, Interventional Neuroradiology, Medical device

RapidPulse is a spin-out of Syntheon 2.0, LLC, an innovative medical device incubator with a long track record of successful exits.

Key Points: 
  • RapidPulse is a spin-out of Syntheon 2.0, LLC, an innovative medical device incubator with a long track record of successful exits.
  • In this study, 40 patients were enrolled in the RapidPulse arm and treated using an 0.071-inch catheter.
  • The investigators used commercially available aspiration catheters ranging in size from 0.070 to 0.072 to treat the control arm patients with standard aspiration pumps.
  • Dr. Serdar Geyik from Istanbul's Aydin University commented, “This is an exciting improvement for the treatment of ischemic stroke due to large vessel occlusion.

New Study Finds Link Between Health Care Disparities and Stroke Treatment

Retrieved on: 
Thursday, February 29, 2024
Social media, United States census, Nervous system, Alzheimer's disease, Doctor of Philosophy, Research, Education, Kahathuduwa, Stroke, Master of Philosophy, Thrombolysis, Health, Annual general meeting, DSM-IV codes, Migraine, AAN, Multiple sclerosis, Parkinson's disease, Medicare, Employment, Concussion, Epilepsy, Medicaid, Brain, Housing, Insurance, American Academy

The study looked at people with ischemic stroke, which is caused by a blockage of blood flow to the brain and is the most common type of stroke.

Key Points: 
  • The study looked at people with ischemic stroke, which is caused by a blockage of blood flow to the brain and is the most common type of stroke.
  • The study involved 63,983 people with ischemic stroke identified through public health records in Texas.
  • Researchers then looked at social factors that may impact a person's health, such as income, education, housing, and access to health services.
  • Further studies are needed to investigate this connection between society, the health care system, and stroke outcomes.

Human medicines European public assessment report (EPAR): Clopidogrel Viatris (previously Clopidogrel Taw Pharma), clopidogrel, Date of authorisation: 16/10/2009, Revision: 27, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, Acute coronary syndrome, Thrombolysis, Artery, Moyamoya disease, INN, Risk, ABCD2, ATC, Myocardial infarction, Bleeding, International, Blood, ASA, Brain, NIHSS, Language, Heart, TIA, Vitamin K, Vascular disease, Percutaneous coronary intervention, European Medicines Agency, VKA, Preventive healthcare, Tablet, ADP, Select, Chest pain, Aspirin, Patient, Anatomy, IIA, Atrial fibrillation, Generic drug

Human medicines European public assessment report (EPAR): Clopidogrel Viatris (previously Clopidogrel Taw Pharma), clopidogrel, Date of authorisation: 16/10/2009, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Clopidogrel Viatris (previously Clopidogrel Taw Pharma), clopidogrel, Date of authorisation: 16/10/2009, Revision: 27, Status: Authorised

Late-Breaking Clinical Trial Results Announced at The VEINS 2023

Retrieved on: 
Monday, October 30, 2023
Trial of the century, RCT, Male, The, Thrombolysis, Dexamethasone, VIVID, PE, DVT, Hemodynamics, BPM, Deep vein thrombosis, PTS, VIVA, Safety, Patient, Ageing, Contraindication, Heart rate, CTA, Research, Quality of life, Syndrome, Anesthesia, Education, Villalta, USP, Freedom, Randomized controlled trial, Wynn Las Vegas, Birth control, Medical imaging, Pharmaceutical industry, Akura, Bullfrog

Below are highlights of this morning's 4 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 4 late-breaking clinical trial presentations.
  • These favorable clinical outcomes highlight the need for randomized controlled trial data comparing MT with standard of care anticoagulation treatment.
  • In the second phase of the trial, 60 participants will be enrolled 1:1 in a dual-blinded, randomized controlled trial (RCT).
  • Of the 21 patients followed at 1 month, 19 (90.5%) had fully compressible and two had partially compressible common femoral veins.

Advances in Stroke Disease Market Insights: Expediting Drug Development, Epidemiology Study, Clinical Trial and Pipeline Assessment with DLI's Healthcare Consulting Services | Disease Landscape Insights

Retrieved on: 
Wednesday, October 11, 2023
Diagnosis, Walking, Smoking, Drug development, Centers for Disease Control and Prevention, Death, Stroke, Aspirin, Bleeding, Cell death, Public, Medicine, Prevalence, Brain, Factor, Intraparenchymal hemorrhage, Therapy, DSM-IV codes, Brain damage, Arm, Grim – Stroke – Disease, Diabetes, Headache, Sleep deprivation, Rehabilitation, Weakness, Speech, Signs and symptoms, Plaque, Dizziness, Leg, Hypoesthesia, Thrombolysis, Confusion, DLI, Face, Patient, Risk, Dietary supplement, Pharmaceutical industry

According to a stroke statistic released by the Center for Disease Control and Prevention, a person dies of stroke in every 3 minutes and 14 seconds worldwide.

Key Points: 
  • According to a stroke statistic released by the Center for Disease Control and Prevention, a person dies of stroke in every 3 minutes and 14 seconds worldwide.
  • There are two primary types of strokes, i.e., ischemic and haemorrhagic stroke.
  • Ishemic stroke which occurs when a blood clot or plaque buildup narrows or blocks an artery supplying blood to the brain.
  • DLI's healthcare consulting services have been instrumental in advancing the understanding of stroke disease, expediting drug development, conducting epidemiological research, assessing clinical trials, and broadening product offerings.

Advances in Stroke Disease Market Insights: Expediting Drug Development, Epidemiology Study, Clinical Trial and Pipeline Assessment with DLI's Healthcare Consulting Services | Disease Landscape Insights

Retrieved on: 
Wednesday, October 11, 2023
Diagnosis, Walking, Smoking, Drug development, Centers for Disease Control and Prevention, Death, Stroke, Aspirin, Bleeding, Cell death, Public, Medicine, Prevalence, Brain, Factor, Intraparenchymal hemorrhage, Therapy, DSM-IV codes, Brain damage, Arm, Grim – Stroke – Disease, Diabetes, Headache, Sleep deprivation, Rehabilitation, Weakness, Speech, Signs and symptoms, Plaque, Dizziness, Leg, Hypoesthesia, Thrombolysis, Confusion, DLI, Face, Patient, Risk, Dietary supplement, Pharmaceutical industry

According to a stroke statistic released by the Center for Disease Control and Prevention, a person dies of stroke in every 3 minutes and 14 seconds worldwide.

Key Points: 
  • According to a stroke statistic released by the Center for Disease Control and Prevention, a person dies of stroke in every 3 minutes and 14 seconds worldwide.
  • There are two primary types of strokes, i.e., ischemic and haemorrhagic stroke.
  • Ishemic stroke which occurs when a blood clot or plaque buildup narrows or blocks an artery supplying blood to the brain.
  • DLI's healthcare consulting services have been instrumental in advancing the understanding of stroke disease, expediting drug development, conducting epidemiological research, assessing clinical trials, and broadening product offerings.

Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)

Retrieved on: 
Monday, September 18, 2023
Research, General Health, Pharmaceutical, Oncology, Clinical Trials, Science, Surgery, Cardiology, Biotechnology, FDA, Other Science, Health, VTE, Bleeding, Factor XI, National Blood Clot Alliance, Medicine, Atrial fibrillation, Data monitoring committee, The New England Journal of Medicine, Stroke, Xi, DOAC, Harvard Medical School, CDC, Thrombosis, Anticoagulant, Gold, Coronary thrombosis, Patient, Myocardial infarction, Risk, Rivaroxaban, Thrombolysis, TIMI, Pravastatin or atorvastatin evaluation and infection therapy - thrombolysis in myocardial infarction 22, Hospital, Congress, MPH, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Centers for Disease Control and Prevention, Pharmaceutical industry, Brigham, MD

The study has been stopped early by the Data Monitoring Committee due to an overwhelming reduction in the composite of major and clinically relevant non-major bleeding in patients taking abelacimab compared with patients taking rivaroxaban, a leading standard-of-care DOAC.

Key Points: 
  • The study has been stopped early by the Data Monitoring Committee due to an overwhelming reduction in the composite of major and clinically relevant non-major bleeding in patients taking abelacimab compared with patients taking rivaroxaban, a leading standard-of-care DOAC.
  • In addition, abelacimab is the first and only Factor XI inhibitor to demonstrate an unprecedented reduction in major bleeding compared to a DOAC, which is the most serious type of bleeding.
  • “The AZALEA-TIMI 71 study is the largest and longest head-to-head study of a Factor XI inhibitor to provide definitive evidence of a highly significant reduction in bleeding as compared to the standard-of-care anticoagulant.
  • Abelacimab 150 mg maintains ~98% inhibition over the dosing interval, recapitulating the benign bleeding profile of patients with genetic Factor XI deficiency.

Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616

Retrieved on: 
Friday, August 25, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, MSD, Myocardial infarction, Amputation, Week, Cardiovascular disease, MRK, Lipid, Merck & Co., Harvard Medical School, Hypercholesterolemia, MD, Patient, Physician, Risk, LDL, PCSK9, Thrombolysis, Buerger's test, ASCVD, Moyamoya disease, Hospital, Death, NYSE, TIMI, Stroke, Pharmaceutical industry, Medicine, Brigham, Merck

This is the first Phase 3 clinical program for an oral PCSK9 inhibitor.

Key Points: 
  • This is the first Phase 3 clinical program for an oral PCSK9 inhibitor.
  • Merck also plans to initiate a Phase 3 cardiovascular outcomes study, CORALreef Outcomes by the end of 2023.
  • Merck is collaborating with the TIMI Study Group, a leading academic research organization for cardiovascular clinical trials, on the CORALreef Outcomes study.
  • Merck’s broad, global Phase 3 program for MK-0616 aims to enroll approximately 17,000 participants across the CORALreef Lipids, CORALreef HeFH and CORALreef Outcomes studies.

Viz.ai to Expedite Patient Enrollment in NIH-funded PE-TRACT Clinical Trial

Retrieved on: 
Saturday, March 4, 2023
Surgery, Medical Devices, Clinical Trials, Health Technology, Cardiology, Practice Management, Biotechnology, Biometrics, Health, Pulmonary embolism, National Heart, Lung, and Blood Institute, Patient, Viz, AI, Faculty, Clinical trial, Workflow, Anticoagulant, Lung, Thrombolysis, Interventional radiology, Weill Cornell Medicine, Bangladesh Technical Education Board, Research, Triage, Medical imaging, Pharmaceutical industry

The PE-TRACT trial will be the most rigorous randomized controlled clinical trial to date of catheter-directed therapy for pulmonary embolism, with plans to enroll 500 patients across 30-50 sites.

Key Points: 
  • The PE-TRACT trial will be the most rigorous randomized controlled clinical trial to date of catheter-directed therapy for pulmonary embolism, with plans to enroll 500 patients across 30-50 sites.
  • Viz.ai’s RECRUIT tool has the potential to efficiently identify potential participants and help this important trial complete enrollment on time.”
    Participating research institutions in the PE-TRACT trial will use Viz RECRUIT to find, screen, and enroll clinical trial candidates.
  • “We’re honored to be the partner of choice for this clinical trial to accelerate vascular research using Viz RECRUIT.
  • With our platform’s real-world accuracy and demonstrated success, researchers can use AI to identify potentially eligible trial candidates, regardless of their location, ultimately expediting the clinical trial enrollment process,” said Jayme Strauss, chief clinical officer, Viz.ai.

Basking Biosciences to Present Clinical Trial Results on First Reversible Thrombolytic Agent at American Heart Association International Stroke Conference 2023

Retrieved on: 
Tuesday, January 31, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, American Heart, Von Willebrand factor, Blood, RNA, University, Drug-induced QT prolongation, ISC, Safety, University of Pittsburgh, Bleeding, Conference, Thrombolysis, Doctor of Philosophy, Pharmaceutical industry, Stroke, Pharmacokinetics, Tolerability

Basking Biosciences, a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapeutic for ischemic stroke, today announced the company will be presenting three oral presentations and two moderated posters concerning the company’s novel drug candidate at the American Heart Association’s 2023 International Stroke Conference (ISC).

Key Points: 
  • Basking Biosciences, a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapeutic for ischemic stroke, today announced the company will be presenting three oral presentations and two moderated posters concerning the company’s novel drug candidate at the American Heart Association’s 2023 International Stroke Conference (ISC).
  • The ISC is being held both live and virtually from February 8-10 in Dallas, Texas.
  • “Current drug treatments for acute ischemic stroke have been restricted by a narrow therapeutic window and high risk of bleeding.
  • It is a rapid-onset, short-acting thrombolytic agent that is capable of recanalizing blocked blood vessels within a greatly extended therapeutic window than current therapy.”